1. Most Discussed
  2. Gainers & Losers
BLT 18.5¢

AAV8 doing its job

  1. Hoyland

    3,824 Posts.
    There has been speculation in some quarters that the AAV8 vector used for TT-034 may not be an efficient vector. We will soon know the real answer to this question. However, in between time, results from other trials using AAV8 could be a guide to the possible outcome for TT-034.

    Earlier this week, Baxter released some preliminary results from its haemophilia B trial. This trial uses AAV8 in a dose escalation study. It started recruiting at about 10 US sites in early 2013. By the end of 2014, 6 patients had been treated in 3 cohorts. So far, only one patent has had in immune response and that patient was treated with oral corticosteroids. That patient was one of those administered with the highest dose to-date.

    There is clearly more work being done as the highest doses in the trial (the last ten patients) are yet to be administered. These results are, therefore, not final but they tend to suggest that the AAV8 vector is doing its job in the liver.

    The vector that Baxter is using is (I believe) a more refined/engineered vector than that used for TT-034 but, nevertheless, these results do indicate that a therapeutic transfection rate of the TT-034 AAV vector could be achieved. Good news in the lead up to Benitec's next announcement.

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.